权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Modulating retinal lipid biogenesis in diabetes for therapeutic effects

调节糖尿病视网膜脂质生物合成以获得治疗效果

基本信息

批准号：
10672366
负责人：
Rithwick Rajagopal
金额：
$ 38.88万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10672366
关键词：
ATF6 gene Ablation Acceleration Acetyl-CoA Carboxylase Address Adenosine Monophosphate Adult Affect Agonist Agreement Anabolism Biogenesis Blindness Calcium Catabolism Cells Cellular Stress Clinical Data Development Diabetes Mellitus Diabetic Retinopathy Disease Endoplasmic Reticulum Enzymes Fatty-acid synthase Glucose Goals Health Homeostasis Human Hyperglycemia Image Injury Ion Channel Link Lipids Mammalian Cell Mass Spectrum Analysis Medium chain fatty acid Metabolic Metabolism Metformin Modeling Modernization Modification Molecular Onset of illness Palmitates Palmitic Acids Pathogenesis Pathologic Pathology Pathway interactions Patients Pattern Phosphotransferases Photoreceptors Post-Translational Protein Processing Prevalence Process Production Proteins Public Health Reporting Retina Retinal Diseases Rod Ryanodine Receptor Calcium Release Channel Severities Signal Transduction Signaling Molecule Stress Testing Therapeutic Effect Tissues Transgenic Organisms Vision Visual Visual impairment calcium indicator cost diabetic disability endoplasmic reticulum stress experimental study gain of function genetic manipulation improved inhibitor lipid biosynthesis lipid metabolism new therapeutic target non-diabetic novel palmitoylation prevent public health relevance release of sequestered calcium ion into cytoplasm retinal rods targeted treatment therapy development visual cycle

项目摘要

Project Summary Diabetic retinopathy is an increasingly common cause of visual impairment and blindness among adults. Modern therapy has become increasingly effective, but remains insufficient to prevent vision loss in a sizable proportion of patients. Early-acting and efficacious new remedies are needed, especially since the prevalence of worldwide disease is increasing. A barrier to accomplishing this goal is a poor understanding of the earliest causes of retinal injury in diabetes. In this application, we will address this barrier by studying early changes in retinal metabolism during diabetes – changes that are likely to contribute to disease onset and that can be targeted for therapeutic purposes. Hyperglycemia is the hallmark of all forms of diabetes and is directly related to its complications, including diabetic retinopathy. Since glucose is the primary fuel of the retina, we investigated what pathological effects might occur due to its excess supply in diabetes. Specifically, we discovered that diabetes is associated with a fundamental shift in retinal metabolism away from tissue break down (catabolism) and towards tissue building (anabolism). Among the largest changes is that of lipid biosynthesis, a pathway responsible for generating a ubiquitous medium-chain fatty acid in mammalian cells, palmitate. In diabetes, retinal palmitate synthesis is elevated by 70% compared to non-diabetic controls. Using targeted genetic manipulation of the enzymes in the synthesis pathway, we determined that reduction of palmitate prevents vision loss in diabetes whereas elevating its production accelerates the onset of visual abnormalities. We now ask how such signals are related to disease development and what specific molecules are involved. Towards these goals, we recently found that excess palmitate in the diabetic retina impacts several retinal enzymes that are regulated by S-palmitoylation. The largest change was seen in retinal Ryanodine Receptor 2 (Ryr2) – an intracellular ion channel that regulates calcium homeostasis – as it is hyper-palmitoylated in diabetes compared to non-diabetic controls. In this application we will determine whether this molecular change is associated with pathology and whether it can be reversed for therapeutic effects. We will address three major aims: (1) define the effect of diabetes on retinal Ryr2 palmitoylation and its functional consequences; (2) delineate whether Ryr2-associated calcium flux in rods is dependent on retinal lipid biogenesis; and (3) determine whether improving retinal lipogenic signaling in diabetes reduces diabetic retinopathy severity. By accomplishing these aims, we could uncover essential root causes of diabetic retinopathy and we may introduce novel targets for therapy directed at a very early stage of the disease process.

项目总结